G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

(2022) Ryunosuke Nakagawa et al.   Frontiers in Oncology

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

(2022) Christian Pfister et al.   JOURNAL OF CLINICAL ONCOLOGY

Supportive care in patients with cancer during the COVID-19 pandemic

(2021) M. Aapro et al.   ESMO Open

The Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19 Infection

(2021) Allen W Zhang et al.   CLINICAL INFECTIOUS DISEASES

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis

(2021) María Sereno et al.   Cancers

Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research

(2021) Angioletta Lasagna et al.   Immunotherapy

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death

(2020) Ramón Yarza et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study

(2020) Hartmut Link et al.   SUPPORTIVE CARE IN CANCER

Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper

(2020) Tim Cooksley et al.   SUPPORTIVE CARE IN CANCER

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

(2019) Julia Bohlius et al.   JOURNAL OF CLINICAL ONCOLOGY

Anemia of Inflammation

(2019) Tomas Ganz   NEW ENGLAND JOURNAL OF MEDICINE

Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years

(2019) John Edelsberg et al.   CURRENT MEDICAL RESEARCH AND OPINION

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors

(2018) Edmond M. Kwan et al.   Clinical Genitourinary Cancer

The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor

(2018) Maja D. Andersen et al.   LEUKEMIA & LYMPHOMA

Risk of pulmonary toxicity of bleomycin and filgrastim

(2018) Magali Laprise-Lachance et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

(2017) Mario Eisenberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

(2017) Stéphane Oudard et al.   JOURNAL OF CLINICAL ONCOLOGY

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

(2017) Gary H. Lyman et al.   SUPPORTIVE CARE IN CANCER

NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim

(2017) Jeffrey J. Kirshner et al.   SUPPORTIVE CARE IN CANCER

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals

(2017) Michael F. Leahy et al.   TRANSFUSION

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events

(2017) T Christopher Bond et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†

(2016) J. Klastersky et al.   ANNALS OF ONCOLOGY

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia

(2016) Irwin Gross et al.   JOURNAL OF CLINICAL ONCOLOGY

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor

(2016) Derek Weycker et al.   SUPPORTIVE CARE IN CANCER

Long-term Survival With Paclitaxel and Gemcitabine for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant

(2015) Brian P. Mulherin et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN

(2015) R. C. F. Leonard et al.   ANNALS OF ONCOLOGY

The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy

(2015) G. H. Lyman et al.   ANNALS OF ONCOLOGY

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data

(2014) J Bohlius et al.   BRITISH JOURNAL OF CANCER

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

(2014) Alena M. Pfeil et al.   SUPPORTIVE CARE IN CANCER

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta-analysis and Systematic Review

(2013) Shelley R. Salpeter et al.   AMERICAN JOURNAL OF MEDICINE

The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question

(2013) L. K. Hicks et al.   BLOOD

Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia

(2013) Maureen J. Aarts et al.   JOURNAL OF CLINICAL ONCOLOGY

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

(2013) Pirkko-Liisa Kellokumpu-Lehtinen et al.   LANCET ONCOLOGY

Transfusion Strategies for Acute Upper Gastrointestinal Bleeding

(2013) Càndid Villanueva et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

(2013) Hartmut Link et al.   ONKOLOGIE

Transfusion guidelines: when to transfuse

(2013) Z. M. Szczepiorkowski et al.   Hematology-American Society of Hematology Education Program

Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials

(2012) Anat Gafter-Gvili et al.   ACTA ONCOLOGICA

Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base

(2012) Jeffrey J. Kirshner et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

(2012) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepcidin and iron regulation, 10 years later

(2011) T. Ganz   BLOOD

Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

(2011) Matti Aapro et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study

(2011) Khaled M Musallam et al.   LANCET

Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery

(2011) Jeffrey L. Carson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies

(2010) J. J. Castillo et al.   BLOOD

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia

(2010) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study

(2010) Frank V. Mortensen et al.   TRANSFUSION

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

(2008) Laurent Bastit et al.   JOURNAL OF CLINICAL ONCOLOGY